Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.38 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL716701 | 0.84 | ADRB2 (0.41) | SLC2A1HTR3ADRD2MAPTKMT2A | |
| SCHEMBL10695866 | 0.84 | MAP1LC3B (0.38) | DRD2MEN1KMT2AMAP1LC3BHTR1A | |
| SCHEMBL10695315 | 0.82 | SLC18A3 (0.37) | CYP2C9HPGDSLC18A3POLB | |
| SCHEMBL9810698 | 0.81 | SLC18A3 (0.44) | MAPTKMT2AHPGDIDO1SLC18A3 | |
| SCHEMBL14864487 | 0.78 | NPC1 (0.38) | MAPTLMNATP53MAP1LC3BSLC18A3 | |
| SCHEMBL315186 | 0.78 | HTR3A (0.58) | SLC2A1HTR3ADRD2MAPTMEN1 | |
| SCHEMBL9347324 | 0.77 | SLC18A3 (0.45) | MAPTLMNAIDO1SLC18A3ALDH1A1 | |
| SCHEMBL5271028 | 0.76 | HTR3A (0.44) | SLC2A1HTR3ADRD2MAPTMEN1 | |
| SCHEMBL8972206 | 0.76 | HTR3A (0.44) | SLC2A1HTR3ADRD2MAPTMEN1 | |
| SCHEMBL23578560 | 0.74 | HTR3A (0.50) | SLC2A1HTR3ADRD2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598387-B2 | Process for the preparation of atovaquone | GLAXO GROUP LIMITED (GB) | 2013-12-03 | — | — | US | claimed |
| EP-2651868-A2 | PROCESS FOR THE PREPARATION OF ATOVAQUONE | Glaxo Group Limited (GB) | 2013-10-23 | — | — | EP | claimed |
| US-20130267717-A1 | PROCESS FOR THE PREPARATION OF ATOVAQUONE | GLAXO GROUP LIMITED (GB) | 2013-10-10 | — | — | US | claimed |
| WO-2012080243-A2 | NOVEL PROCESS | GLAXO GROUP LIMITED (GB) | 2012-06-21 | — | — | WO | claimed |
| WO-2010023686-A2 | CRYSTALLINE FORM OF 2-CHLORO-3-[4-(4-CHLOROPHENYL) CYCLOHEXYL] [1,4]NAPHTHOQUINONE, PROCESS FOR THE SAME AND USE FOR PRODUCING 2-[4-(4-CHLOROPHENYL)CYCLOHEXYL]-3- HYDROXY- 1,4- NAPHTHOQUINONE | MATRIX LABORATORIES LIMITED (IN) | 2010-03-04 | — | — | WO | claimed |
| WO-2009007991-A2 | A NEW PROCESS FOR PREPARATION OF ATOVAQUONE AND NOVEL INTERMEDIATES THEREOF | IPCA LABORATORIES LIMITED (IN) | 2009-01-15 | — | — | WO | claimed |
| CN-110734369-B | Preparation method of atovaquone | 新发药业有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-110734369-A | Preparation method of atovaquones | 新发药业有限公司 | 2020-01-31 | — | — | CN | disclosed |
| US-8598387-B2 | Process for the preparation of atovaquone | GLAXO GROUP LIMITED (GB) | 2013-12-03 | — | — | US | disclosed |
| EP-2651868-A2 | PROCESS FOR THE PREPARATION OF ATOVAQUONE | Glaxo Group Limited (GB) | 2013-10-23 | — | — | EP | disclosed |
| US-8283499-B2 | Preparation of naphthoquinone compounds using 2,3-dihalonaphthoquinone | ALKEM LABORATORIES LIMITED (IN) | 2012-10-09 | — | — | US | disclosed |
| WO-2012080243-A2 | NOVEL PROCESS | GLAXO GROUP LIMITED (GB) | 2012-06-21 | — | — | WO | disclosed |
| US-7985755-B2 | 2,4-diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2011-07-26 | — | — | US | disclosed |
| WO-2009007991-A2 | A NEW PROCESS FOR PREPARATION OF ATOVAQUONE AND NOVEL INTERMEDIATES THEREOF | IPCA LABORATORIES LIMITED (IN) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008122988-A1 | PROCESS FOR PREPARATION OF ATOVAQUONE AND THE CONVERSION OF CIS-ISOMER TO TRANS- ISOMER | CADILA HEALTHCARE LIMITED (IN) | 2008-10-16 | — | — | WO | disclosed |
| US-20060178403-A1 | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-08-10 | — | — | US | disclosed |
| WO-2004081005-A1 | MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AND COMPOSITIONS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2004-09-23 | — | — | WO | disclosed |
| EP-0102047-B1 | 1-(TRANS-4-ALKYLCYCLOHEXYL)-2-(TRANS-4'-(P-SUBSTITUTED PHENYL)CYCLOHEXYL)ETHANE AND LIQUID CRYSTAL MIXTURE | ASAHI GLASS COMPANY LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
| US-4514044-A | 1-(Trans-4-alkylcyclohexyl)-2-(trans-4'-(p-substituted phenyl) cyclohexyl)ethane and liquid crystal mixture | ASAHI GLASS COMPANY LTD. (JP) | 1985-04-30 | — | — | US | disclosed |
| EP-0102047-A1 | 1-(Trans-4-alkylcyclohexyl)-2-(trans-4'-(p-substituted phenyl)cyclohexyl)ethane and liquid crystal mixture | ASAHI GLASS COMPANY LTD. (JP) | 1984-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178403-A1 | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | MCHR1, MCHR2, MC1R | SLC2A1 1168/4885HTR3A 77/4885DRD2 517/4885 |
| US-20130267717-A1 | PROCESS FOR THE PREPARATION OF ATOVAQUONE | DHPS, VKORC1, DPYD | SLC2A1 2286/4885HTR3A 3301/4885DRD2 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.